Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
Abstract Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20/anti-CD3 BsAb, is an exciting new option for...
محفوظ في:
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMC
2023-06-01
|
| سلاسل: | Journal of Hematology & Oncology |
| الوصول للمادة أونلاين: | https://doi.org/10.1186/s13045-023-01462-0 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|